Skip to main content
Optimind Pharma Corp. logo

Optimind Pharma Corp. — Investor Relations & Filings

Ticker · OMND ISIN · CA68405U1012 CSE Human health and social work activities
Open in API
Filings indexed 134 across all filing types
Latest filing 2025-09-08 M&A Activity
Country CA Canada
Listing CSE OMND

About Optimind Pharma Corp.

https://optimindpharma.com

Optimind Pharma Corp. is a provider specializing in psychedelic therapies and alternative treatments for mental health disorders. The company focuses on addressing conditions such as Post-Traumatic Stress Disorder (PTSD), anxiety, and depression. Optimind's core offerings include Psychedelic-Enhanced Psychotherapy (PEP) and Ketamine-Assisted Treatment (KAT). The treatment modalities encompass both monotherapy and assisted therapy, frequently utilizing ketamine capsules to facilitate therapeutic outcomes. Additionally, the company provides services related to the prescription of medical cannabis, integrating these various approaches to deliver comprehensive mental wellness solutions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
M&A Activity Classification · 90% confidence The document is a press release announcing a binding definitive share exchange agreement that constitutes a fundamental change of business, including details on the transaction structure, share issuance, and conditions precedent. This corresponds to an M&A activity announcement rather than a general financing update or report publication. Therefore, the correct classification is M&A Activity (TAR).
2025-09-08 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 82% confidence The document is a ‘‘Venture Issuer Basic Certificate’’ under Canadian NI 52-109, certifying the interim financial report and MD&A for the period ended May 31, 2025. It is not the actual interim report (IR) or an annual report (10-K), nor is it an earnings release or management discussion. It is a regulatory certification form, which does not fit any specialized category and thus falls under the fallback category for general regulatory filings.
2025-07-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a Form 52-109FV2 certification by the CFO under Canadian NI 52-109 for interim filings. It is a regulatory certification form rather than the interim financial report itself, an MD&A, or an announcement of a report. It does not fit specialized categories like audit, earnings release, or interim/quarterly report content. It therefore falls into the general Regulatory Filings category.
2025-07-30 English
Interim MD&A - English.pdf
Management Reports Classification · 93% confidence The document is titled “Management Discussion and Analysis” for the three months ended May 31, 2025, providing management’s explanation of financial results, business trends, risks, and outlook. It is an unaudited interim MD&A prepared in accordance with IFRS and intended to accompany the condensed interim financial statements. This corresponds directly to our definition of Management Reports (Code: MDA).
2025-07-30 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for the three months ended May 31, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Shareholders' Deficiency, and Statement of Cash Flows) along with detailed notes to the financial statements. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q2 2025
2025-07-30 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a certification form (Form 52-109FV1) under NI 52-109, signed by the CEO certifying the review of the annual filings (AIF, financial statements, MD&A) for the year ended February 28, 2025. It does not itself contain the financial statements, management discussion, or detailed results, nor is it an investor presentation or proxy material. It is a regulatory certificate filing, so it falls into the fallback category of general regulatory filings.
2025-06-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.